Alemtuzumab plus Fludarabine

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Leukemia, Lymphocytic, Chronic, B-Cell

Drug Information

Target Indication

Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trial

Last updated: 12/10/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Related Pipeline

Asthma

Multiple Sclerosis

Asthma

Atrial Fibrillation

Embolism

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts